These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 7984223)
1. Italian drug firms rethink ban on conference support. Feder T Nature; 1994 Dec; 372(6505):392. PubMed ID: 7984223 [No Abstract] [Full Text] [Related]
2. American Psychiatric Association says no to industry funding for symposiums. Tanne JH BMJ; 2009 Apr; 338():b1426. PubMed ID: 19349347 [No Abstract] [Full Text] [Related]
3. Sponsored medical education? Nagral S Issues Med Ethics; 1998 Jan; 6(1):3. PubMed ID: 16267919 [No Abstract] [Full Text] [Related]
4. [The "to be or not to be" of the scientific congresses. Reduced resources and virtual meetings hit against pleasure-trips]. Rössner S Lakartidningen; 2003 Mar; 100(11):952-5. PubMed ID: 15148723 [No Abstract] [Full Text] [Related]
5. Of doctor conventions and drug companies. Standridge JB Fam Med; 2006; 38(7):518-20. PubMed ID: 16823679 [TBL] [Abstract][Full Text] [Related]
7. Dealing with drug dependency: a commentary on ILAE's partnership with the pharmaceutical industry. Avanzini G; Engel J Epilepsia; 2007 Oct; 48(10):1821-4. PubMed ID: 17683507 [No Abstract] [Full Text] [Related]
8. Response to Drs. Katz and Carey: North American Conference of Gastroenterology Fellows. Gitkind MJ Am J Gastroenterol; 1995 Apr; 90(4):671. PubMed ID: 7717340 [No Abstract] [Full Text] [Related]
9. Expenses for meetings and fees for service: details of 'disclosure' required of pharmaceutical companies. Shurlock B Eur Heart J; 2013 Dec; 34(47):3589-90. PubMed ID: 24335158 [No Abstract] [Full Text] [Related]
10. Premier funds biotechnology. Scott L Mod Healthc; 1996 Apr; 26(18):50. PubMed ID: 10157168 [No Abstract] [Full Text] [Related]
11. More on scientific assembly drug company support. Rosenblatt RA Fam Med; 2006; 38(10):690. PubMed ID: 17075736 [No Abstract] [Full Text] [Related]
13. Support for commentary on AAFP scientific assembly. Feldman E Fam Med; 2006; 38(10):690. PubMed ID: 17075737 [No Abstract] [Full Text] [Related]
14. Japanese firms broaden investment focus to early biotech. Louët S; Sipp D Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631 [No Abstract] [Full Text] [Related]
15. [Sponsoring of medical congresses: a unproblematic problem?]. Melzer S Unfallchirurg; 2010 Feb; 113(2):164. PubMed ID: 20108083 [No Abstract] [Full Text] [Related]
16. [Congresses, meetings and events. Which route do we take?]. González González J Semergen; 2014 Oct; 40(7):410. PubMed ID: 24837527 [No Abstract] [Full Text] [Related]
17. Take a meeting. Drug firms hosting many more events for docs. Romano M Mod Healthc; 2001 Jul; 31(29):9. PubMed ID: 11484239 [No Abstract] [Full Text] [Related]
18. Industry funding of patients' support groups: declaration of competing interests is rare in Italian breast cancer associations. Mosconi P BMJ; 2003 Aug; 327(7410):344. PubMed ID: 12907506 [No Abstract] [Full Text] [Related]
20. Obesity task force linked to WHO takes "millions" from drug firms. Moynihan R BMJ; 2006 Jun; 332(7555):1412. PubMed ID: 16777884 [No Abstract] [Full Text] [Related] [Next] [New Search]